Login / Signup

Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation.

Gregg W StoneWilliam T AbrahamJoAnn LindenfeldSaibal KarPaul A GrayburnD Scott LimJacob M MishellBrian WhisenantMichael RinaldiSamir R KapadiaVivek RajagopalIan J SarembockAndreas BriekeSteven O MarxDavid J CohenFederico M AschMichael J Macknull null
Published in: The New England journal of medicine (2023)
Among patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite guideline-directed medical therapy, transcatheter edge-to-edge repair of the mitral valve was safe and led to a lower rate of hospitalization for heart failure and lower all-cause mortality through 5 years of follow-up than medical therapy alone. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079.).
Keyphrases
  • mitral valve
  • heart failure
  • healthcare
  • early onset
  • left ventricular
  • left atrial
  • mesenchymal stem cells
  • bone marrow
  • drug induced
  • cardiac resynchronization therapy